Taysha Gene Therapies, Inc. TSHA
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 171.27% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 171.27% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | 171.27% | -- |
| SG&A Expenses | 58.30% | 41.27% | 18.62% | 33.25% | 4.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.07% | 76.70% | 83.31% | 53.89% | 48.91% |
| Operating Income | -23.07% | -89.82% | -103.01% | -41.98% | -61.56% |
| Income Before Tax | -19.54% | -73.50% | -96.99% | -48.26% | -28.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.54% | -73.50% | -96.99% | -48.26% | -28.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.54% | -73.50% | -96.99% | -48.26% | -28.24% |
| EBIT | -23.07% | -89.82% | -103.01% | -41.98% | -61.56% |
| EBITDA | -23.35% | -90.70% | -104.33% | -42.66% | -62.47% |
| EPS Basic | -4.00% | -40.13% | -44.81% | -11.29% | 2.83% |
| Normalized Basic EPS | -5.98% | -54.22% | -50.43% | -7.76% | -24.60% |
| EPS Diluted | -4.00% | -40.13% | -44.81% | -11.29% | 2.83% |
| Normalized Diluted EPS | -5.98% | -54.22% | -50.43% | -7.76% | -24.60% |
| Average Basic Shares Outstanding | 14.94% | 23.84% | 36.14% | 33.14% | 31.92% |
| Average Diluted Shares Outstanding | 14.94% | 23.84% | 36.14% | 33.14% | 31.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |